Labcorp Holdings Inc. reported financial results for the third quarter ended September 30, 2026, and updated its full-year outlook. For the quarter, total revenue reached $3.81 billion, an increase of 6.9% compared to the prior year period. Diluted earnings per share (EPS) were $3.22, up 3.3% year-over-year, while adjusted EPS rose 14.5% to $4.78.
On a nine-month basis, total revenue for 2026 was $11.08 billion, a 6.2% increase from $10.44 billion in 2025. Adjusted EPS for the first nine months of 2026 was $14.02, compared to $12.37 in the same period of 2025.
The company announced an updated full-year 2026 guidance range for enterprise revenue growth of 5.9% to 6.7%, an increase of 50 basis points at the midpoint from the previous guidance. Adjusted EPS guidance for the full year is now projected to be between $18.30 and $18.70, up 18 cents at the midpoint. Free cash flow guidance remains between $1.24 billion and $1.36 billion.
Labcorp also highlighted strategic developments during the quarter. The company received FDA approval for the PGDx elio tissue complete CDx companion diagnostic to assist in identifying patients with advanced melanoma. Additionally, Labcorp announced four new or completed acquisitions, including the purchase of MLM Medical Labs, and agreements to acquire select assets of BioReference Health’s laboratory testing businesses, the Prenatal Health testing business from Myriad Genetics, and Millennium Health.
Regarding capital allocation, Labcorp invested $255.5 million in acquisitions during the third quarter and paid $58.2 million in dividends. The company declared a quarterly cash dividend of $0.72 per share, payable on December 11, 2026. As of September 30, 2026, Labcorp had $1.4 billion remaining under its board-authorized share repurchase program.
